Advertise
Resources
Member, Beacon International Group, Ltd.
The recent Food and Drug Administration approval of Biogden's Aduhelm, a drug that may slow Alzheimer's conditions, has raised concerns that patient advocacy groups will pressure Medicare and private insurers to cover expensive tests needed to concretely diagnose the disease, Politico reports. Other questions include whether patients will face huge out-of-pocket costs, as well as how successful the drug will be in treating Alzheimer's.